Galimedix Therapeutics has assembled a dedicated Alzheimer's Disease Scientific Advisory Board to steer the clinical development of GAL-101, the company's oral drug candidate. The Phase 2 clinical-stage biotechnology company, which is working on oral and topical neuroprotective therapies for brain and eye diseases, says the panel will provide scientific and clinical guidance as the Alzheimer's program moves forward.
The board's composition points to the specific problems Galimedix expects to face in trials. Andreas Busjahn, PhD, founder and managing director of HealthTwiSt in Berlin, brings biostatistics and data science. Willem de Haan, MD, PhD, a neurologist and senior researcher at the Alzheimer Center Amsterdam, Amsterdam UMC, works on neuronal network dysfunction in Alzheimer's and on EEG-based measures of brain connectivity and treatment effects. John E. Harrison, PhD, professor at King's College London and Amsterdam UMC, chairs the scientific advisory board of Scottish Brain Sciences and serves as clinical vice president at Signant Health, with a long track record in cognitive assessment in dementia.
That mix - cognitive testing, electrophysiology, genetics, biomarkers and statistics - reflects how much of Alzheimer's drug development now hinges on measurement rather than chemistry. Deciding which outcomes to track, how sensitively to track them, and how to interpret noisy cognitive data has sunk more than one promising compound, and companies increasingly recruit that expertise before trials begin rather than after results disappoint.
For patients and families, this is infrastructure news rather than clinical news. No trial results, efficacy data or safety findings for GAL-101 are reported here. What it signals is that Galimedix intends to push the candidate further through clinical development, and that the read-outs to watch will be the trials themselves.